ALSO NOTED: Novartis may hand out cancer drug in Thailand; Abilify gets new use against major depression;

> Novartis may give Thailand free cancer meds if the country lays off its fight to compel drug makers to license generic versions of patented remedies. Report

> Bristol-Myers Squibb's antipsychotic med Abilify got the FDA's nod as an add-on therapy for major depression in patients who don't respond fully to antidepressants alone. Report

> Datamonitor predicts that sales of the Bayer/Onyx drug Nexavar will be "substantially boosted" by its new U.S. approval for treatment of inoperable liver cancer. Report

> Canadian students are abusing prescription painkillers at an unprecedented rate, according to a new survey. Report

And Finally... Need more evidence that stress can be a killer? The stress hormone norepinephrine appear to stimulate tumor-cell growth. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.